Bain Capital Life Sciences Investors, LLC
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.49B2026 Q3
Positions23
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.81.9%
Bain Capital Life Sciences Investors, LLC reported 23 positions worth $1.49B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: KLRA (17.3%).
10 / 23 positions shown
| # | Symbol | Company | Value ↓ | % Port. | Shares | 1Y | YTD | Since reported |
|---|---|---|---|---|---|---|---|---|
| ▸ 1 | KLRA | $257.9M | 17.31% | 22,583,268 | — | — | +10.1% | |
| ▸ 2 | HTFL | $221.3M | 14.85% | 4,448,158 | — | — | -5.8% | |
| ▸ 3 | ADRX | $134.2M | 9.01% | 6,728,970 | — | — | -28.8% | |
| ▸ 4 | ALKS | $127.7M | 8.57% | 3,150,985 | — | — | +14.8% | |
| ▸ 5 | NAMS | $92.6M | 6.21% | 3,806,559 | — | — | -20.0% | |
| ▸ 6 | SVRA | $90.8M | 6.10% | 17,600,621 | — | — | -10.1% | |
| ▸ 7 | TARS | $86.2M | 5.78% | 1,096,141 | — | — | +2.1% | |
| ▸ 8 | PHVS | $76.9M | 5.16% | 2,475,509 | — | — | +2.3% | |
| ▸ 9 | SLDB | $70.9M | 4.76% | 9,808,819 | — | — | -5.4% | |
| ▸ 10 | OLMA | $61.2M | 4.11% | 7,085,249 | — | — | -14.8% |
Read the 2026-Q2 quarterly report · 13F Filing Calendar
Frequently Asked Questions
What stocks does Bain Capital Life Sciences Investors, LLC hold as of Q3 2026?
Bain Capital Life Sciences Investors, LLC reported 23 positions worth $1.49B in its Q3 2026 13F filing. Largest positions: KLRA (17.3%), HTFL (14.9%), ADRX (9.0%), ALKS (8.6%) and NAMS (6.2%).
What did Bain Capital Life Sciences Investors, LLC buy in Q3 2026?
No previous quarter is available yet; the comparison appears with the next filing.
What did Bain Capital Life Sciences Investors, LLC sell in Q3 2026?
No previous quarter is available yet.
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.